{"id":13705,"date":"2026-06-21T08:15:22","date_gmt":"2026-06-21T07:15:22","guid":{"rendered":"https:\/\/blog.caixaresearch.org\/?p=13705"},"modified":"2026-06-18T16:14:22","modified_gmt":"2026-06-18T15:14:22","slug":"news-from-the-lab-i-si-poguessim-frenar-lela","status":"publish","type":"post","link":"https:\/\/blog.caixaresearch.org\/ca\/news-from-the-lab-i-si-poguessim-frenar-lela\/","title":{"rendered":"News from the Lab: I si pogu\u00e9ssim frenar l\u2019ELA?"},"content":{"rendered":"<p><span style=\"font-weight: 400;\">L\u2019esclerosis lateral amiotr\u00f2fica (ELA) \u00e9s una malaltia neurodegenerativa que <\/span><b>destrueix progressivament les neurones responsables del moviment<\/b><span style=\"font-weight: 400;\">. A mesura que avan\u00e7a, els pacients van perdent la capacitat de moure\u2019s, parlar, menjar i fins i tot respirar.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Avui dia encara no existeix cap cura per a aquesta malaltia i els tractaments disponibles nom\u00e9s aconsegueixen alentir-ne lleugerament la progressi\u00f3. Per aix\u00f2, desenvolupar noves ter\u00e0pies \u00e9s <\/span><b>un dels grans reptes de la recerca biom\u00e8dica<\/b><span style=\"font-weight: 400;\">.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Amb aquest objectiu, l\u2019equip liderat per <\/span><a href=\"https:\/\/caixaresearch.org\/ca\/convocatoria-caixaresearch-investigacio-salut-2021-projecte-terapies-ela\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">Ana Mart\u00ednez<\/span><\/a><span style=\"font-weight: 400;\"> i Carmen Gil al Centro de Investigaciones Biol\u00f3gicas Margarita Salas del CSIC fa anys que estudia la TDP-43, una prote\u00efna alterada en m\u00e9s del 97\u2009% dels pacients amb ELA i estretament relacionada amb el progr\u00e9s de la malaltia.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">La seva estrat\u00e8gia ha consistit a desenvolupar la mol\u00e8cula AP-2, dissenyada per restaurar la funci\u00f3 normal d\u2019aquesta prote\u00efna. Els resultats obtinguts fins ara en models cel\u00b7lulars i animals han estat prometedors: <\/span><b>despr\u00e9s de l\u2019administraci\u00f3 del f\u00e0rmac AP-2, la prote\u00efna TDP-43 recupera el seu comportament normal<\/b><span style=\"font-weight: 400;\">, cosa que podria contribuir a alentir la progressi\u00f3 de la malaltia.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Ana Mart\u00ednez i Carmen Gil ens expliquem els \u00faltims aven\u00e7os d\u2019aquesta investigaci\u00f3 en aquest <\/span><b><i>News from The \u201cLab\u201d<\/i><\/b><span style=\"font-weight: 400;\">.<\/span><\/p>\n<p><a href=\"https:\/\/youtu.be\/H7QWY0AUg1Q\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">[V\u00eddeo News from the Lab]<\/span><\/a><\/p>\n<p><span style=\"font-weight: 400;\">Un pas decisiu en aquest cam\u00ed ha estat <\/span><a href=\"https:\/\/www.csic.es\/es\/actualidad-del-csic\/un-farmaco-contra-la-ela-surgido-del-csic-recibe-la-autorizacion-de-la-agencia-espanola-de-medicamentos-para-iniciar-su-ensayo-clinico\" target=\"_blank\" rel=\"noopener\"><span style=\"font-weight: 400;\">la not\u00edcia seg\u00fcent<\/span><\/a><span style=\"font-weight: 400;\">: l\u2019Ag\u00e8ncia Espanyola de Medicaments i Productes Sanitaris <\/span><b>ha autoritzat l\u2019inici de l\u2019assaig cl\u00ednic de fase I del f\u00e0rmac AP-2<\/b><span style=\"font-weight: 400;\">. L\u2019estudi, que va comen\u00e7ar a l\u2019abril, es duu a terme amb la participaci\u00f3 de 70 voluntaris sans i t\u00e9 com a objectiu avaluar la seguretat del tractament.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">A m\u00e9s, l\u2019Ag\u00e8ncia Europea de Medicaments <\/span><b>ha concedit a l\u2019AP-2 la designaci\u00f3 de medicament orfe<\/b><span style=\"font-weight: 400;\">, un reconeixement que impulsa el desenvolupament de noves ter\u00e0pies per a malalties rares.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Si els resultats s\u00f3n positius, el 2027 comen\u00e7ar\u00e0 una nova fase d\u2019assaig amb pacients d\u2019ELA.<\/span><\/p>\n<p><span style=\"font-weight: 400;\">Tot i que encara queda cam\u00ed per rec\u00f3rrer, aquest aven\u00e7 \u00e9s un pas important cap al desenvolupament de <\/span><b>tractaments capa\u00e7os de canviar el futur d\u2019aquesta malaltia<\/b><span style=\"font-weight: 400;\">.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>L\u2019esclerosis lateral amiotr\u00f2fica (ELA) \u00e9s una malaltia neurodegenerativa que destrueix progressivament les neurones responsables del moviment. A mesura que avan\u00e7a, els pacients van perdent la capacitat de moure\u2019s, parlar, menjar i fins i tot respirar.<\/p>\n<p>Avui dia encara no existeix cap cura per a aquesta malaltia i els tractaments disponibles nom\u00e9s aconsegueixen alentir-ne lleugerament la progressi\u00f3. Per aix\u00f2, desenvolupar noves ter\u00e0pies \u00e9s un dels grans reptes de la recerca biom\u00e8dica.<\/p>\n<p>Amb aquest objectiu, l\u2019equip liderat per <a href=\"https:\/\/caixaresearch.org\/ca\/convocatoria-caixaresearch-investigacio-salut-2021-projecte-terapies-ela\" target=\"_blank\" rel=\"noopener\">Ana Mart\u00ednez<\/a> i Carmen Gil al Centro de Investigaciones Biol\u00f3gicas Margarita Salas del CSIC fa anys que estudia la TDP-43, una prote\u00efna alterada en m\u00e9s del 97\u2009% dels pacients amb ELA i estretament relacionada amb el progr\u00e9s de la malaltia.<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[340],"tags":[],"class_list":["post-13705","post","type-post","status-publish","format-standard","hentry","category-sense-categoria"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>News from the Lab: I si pogu\u00e9ssim frenar l\u2019ELA? - Blog CaixaCi\u00e8ncia<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blog.caixaresearch.org\/?p=13703\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"News from the Lab: I si pogu\u00e9ssim frenar l\u2019ELA? - Blog CaixaCi\u00e8ncia\" \/>\n<meta property=\"og:description\" content=\"L\u2019esclerosis lateral amiotr\u00f2fica (ELA) \u00e9s una malaltia neurodegenerativa que destrueix progressivament les neurones responsables del moviment. A mesura que avan\u00e7a, els pacients van perdent la capacitat de moure\u2019s, parlar, menjar i fins i tot respirar. Avui dia encara no existeix cap cura per a aquesta malaltia i els tractaments disponibles nom\u00e9s aconsegueixen alentir-ne lleugerament la progressi\u00f3. Per aix\u00f2, desenvolupar noves ter\u00e0pies \u00e9s un dels grans reptes de la recerca biom\u00e8dica. Amb aquest objectiu, l\u2019equip liderat per Ana Mart\u00ednez i Carmen Gil al Centro de Investigaciones Biol\u00f3gicas Margarita Salas del CSIC fa anys que estudia la TDP-43, una prote\u00efna alterada en m\u00e9s del 97\u2009% dels pacients amb ELA i estretament relacionada amb el progr\u00e9s de la malaltia.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blog.caixaresearch.org\/?p=13703\" \/>\n<meta property=\"og:site_name\" content=\"Blog CaixaCi\u00e8ncia\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-21T07:15:22+00:00\" \/>\n<meta name=\"author\" content=\"Ubikmedia\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ubikmedia\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/blog.caixaresearch.org\/?p=13703\",\"url\":\"https:\/\/blog.caixaresearch.org\/?p=13703\",\"name\":\"News from the Lab: I si pogu\u00e9ssim frenar l\u2019ELA? - Blog CaixaCi\u00e8ncia\",\"isPartOf\":{\"@id\":\"https:\/\/blog.caixaresearch.org\/#website\"},\"datePublished\":\"2026-06-21T07:15:22+00:00\",\"author\":{\"@id\":\"https:\/\/blog.caixaresearch.org\/#\/schema\/person\/2b9d5310c27055b4862191402c387fca\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/blog.caixaresearch.org\/?p=13703\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/blog.caixaresearch.org\/#website\",\"url\":\"https:\/\/blog.caixaresearch.org\/\",\"name\":\"Blog CaixaCi\u00e8ncia\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/blog.caixaresearch.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ca\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/blog.caixaresearch.org\/#\/schema\/person\/2b9d5310c27055b4862191402c387fca\",\"name\":\"Ubikmedia\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/blog.caixaresearch.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ccc66bc497f8ba496f9d06e5a58a91de?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ccc66bc497f8ba496f9d06e5a58a91de?s=96&d=mm&r=g\",\"caption\":\"Ubikmedia\"},\"url\":\"https:\/\/blog.caixaresearch.org\/ca\/author\/ubikmedia\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"News from the Lab: I si pogu\u00e9ssim frenar l\u2019ELA? - Blog CaixaCi\u00e8ncia","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blog.caixaresearch.org\/?p=13703","og_locale":"ca_ES","og_type":"article","og_title":"News from the Lab: I si pogu\u00e9ssim frenar l\u2019ELA? - Blog CaixaCi\u00e8ncia","og_description":"L\u2019esclerosis lateral amiotr\u00f2fica (ELA) \u00e9s una malaltia neurodegenerativa que destrueix progressivament les neurones responsables del moviment. A mesura que avan\u00e7a, els pacients van perdent la capacitat de moure\u2019s, parlar, menjar i fins i tot respirar. Avui dia encara no existeix cap cura per a aquesta malaltia i els tractaments disponibles nom\u00e9s aconsegueixen alentir-ne lleugerament la progressi\u00f3. Per aix\u00f2, desenvolupar noves ter\u00e0pies \u00e9s un dels grans reptes de la recerca biom\u00e8dica. Amb aquest objectiu, l\u2019equip liderat per Ana Mart\u00ednez i Carmen Gil al Centro de Investigaciones Biol\u00f3gicas Margarita Salas del CSIC fa anys que estudia la TDP-43, una prote\u00efna alterada en m\u00e9s del 97\u2009% dels pacients amb ELA i estretament relacionada amb el progr\u00e9s de la malaltia.","og_url":"https:\/\/blog.caixaresearch.org\/?p=13703","og_site_name":"Blog CaixaCi\u00e8ncia","article_published_time":"2026-06-21T07:15:22+00:00","author":"Ubikmedia","twitter_card":"summary_large_image","twitter_misc":{"Escrit per":"Ubikmedia","Temps estimat de lectura":"2 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/blog.caixaresearch.org\/?p=13703","url":"https:\/\/blog.caixaresearch.org\/?p=13703","name":"News from the Lab: I si pogu\u00e9ssim frenar l\u2019ELA? - Blog CaixaCi\u00e8ncia","isPartOf":{"@id":"https:\/\/blog.caixaresearch.org\/#website"},"datePublished":"2026-06-21T07:15:22+00:00","author":{"@id":"https:\/\/blog.caixaresearch.org\/#\/schema\/person\/2b9d5310c27055b4862191402c387fca"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blog.caixaresearch.org\/?p=13703"]}]},{"@type":"WebSite","@id":"https:\/\/blog.caixaresearch.org\/#website","url":"https:\/\/blog.caixaresearch.org\/","name":"Blog CaixaCi\u00e8ncia","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blog.caixaresearch.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ca"},{"@type":"Person","@id":"https:\/\/blog.caixaresearch.org\/#\/schema\/person\/2b9d5310c27055b4862191402c387fca","name":"Ubikmedia","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/blog.caixaresearch.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ccc66bc497f8ba496f9d06e5a58a91de?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ccc66bc497f8ba496f9d06e5a58a91de?s=96&d=mm&r=g","caption":"Ubikmedia"},"url":"https:\/\/blog.caixaresearch.org\/ca\/author\/ubikmedia\/"}]}},"_links":{"self":[{"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/posts\/13705","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/comments?post=13705"}],"version-history":[{"count":4,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/posts\/13705\/revisions"}],"predecessor-version":[{"id":13767,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/posts\/13705\/revisions\/13767"}],"wp:attachment":[{"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/media?parent=13705"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/categories?post=13705"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.caixaresearch.org\/ca\/wp-json\/wp\/v2\/tags?post=13705"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}